Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
LAB

LAB - Standard BioTools Inc. Stock Price, Fair Value and News

2.18USD-0.14 (-6.03%)Market Closed

Market Summary

LAB
USD2.18-0.14
Market Closed
-6.03%

LAB Alerts

  • 1 major insider sales recently.

LAB Stock Price

View Fullscreen

LAB RSI Chart

LAB Valuation

Market Cap

811.3M

Price/Earnings (Trailing)

-9.02

Price/Sales (Trailing)

6.4

EV/EBITDA

-6.61

Price/Free Cashflow

-8.12

LAB Price/Sales (Trailing)

LAB Profitability

EBT Margin

-70.73%

Return on Equity

-15.58%

Return on Assets

-11.57%

Free Cashflow Yield

-12.31%

LAB Fundamentals

LAB Revenue

Revenue (TTM)

126.8M

Rev. Growth (Yr)

81.3%

Rev. Growth (Qtr)

61.56%

LAB Earnings

Earnings (TTM)

-90.0M

Earnings Growth (Yr)

-90.92%

Earnings Growth (Qtr)

-62.61%

Breaking Down LAB Revenue

Last 7 days

11.2%

Last 30 days

6.3%

Last 90 days

-13.5%

Trailing 12 Months

-9.9%

How does LAB drawdown profile look like?

LAB Financial Health

Current Ratio

4.5

Debt/Equity

5e-4

Debt/Cashflow

-325.34

LAB Investor Care

Shares Dilution (1Y)

374.76%

Diluted EPS (TTM)

-1

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024126.8M000
202396.6M105.5M105.2M106.3M
2022124.3M112.0M109.2M97.9M
2021143.3M148.3M136.9M130.6M
2020114.7M112.6M126.0M138.1M
2019117.8M119.6M117.1M117.2M
2018101.7M104.2M108.4M113.0M
2017101.0M96.7M99.3M101.9M
2016117.0M116.5M110.1M104.4M
2015117.5M118.5M117.5M114.7M
201482.4M92.5M103.8M116.5M
201355.9M60.5M66.0M71.2M
201245.1M47.5M49.7M52.3M
201135.5M38.1M40.2M42.9M
2010028.1M30.8M33.6M
200900025.4M

Tracking the Latest Insider Buys and Sells of Standard BioTools Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 28, 2024
cox troy
acquired
-
-
43,128
-
Jun 28, 2024
carey thomas d.
acquired
-
-
43,128
-
Jun 28, 2024
casdin eli
acquired
-
-
43,128
-
Jun 28, 2024
witney frank
acquired
-
-
43,128
-
Jun 28, 2024
hibbs kathy l
acquired
-
-
43,128
-
Jun 28, 2024
eloi fenel m
acquired
-
-
43,128
-
Jun 18, 2024
casdin partners master fund, l.p.
sold
-2,460,000
2.05
-1,200,000
-
Jun 18, 2024
casdin partners master fund, l.p.
acquired
2,460,000
2.05
1,200,000
-
May 23, 2024
casdin partners master fund, l.p.
bought
260,000
2.6
100,000
-
May 22, 2024
casdin partners master fund, l.p.
bought
387,735
2.5849
150,000
-

1–10 of 50

Which funds bought or sold LAB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 16, 2024
MEYER HANDELMAN CO
sold off
-100
-47,425
-
-%
Jul 12, 2024
SG Americas Securities, LLC
added
85.05
14,000
85,000
-%
Jul 10, 2024
CWM, LLC
added
4.57
-8,000
17,000
-%
Jul 01, 2024
Legal & General Group Plc
new
-
522,399
522,399
-%
Jun 11, 2024
EverSource Wealth Advisors, LLC
reduced
-14.39
-2,414
59,024
-%
May 16, 2024
FourWorld Capital Management LLC
new
-
248,507
248,507
0.16%
May 16, 2024
JANE STREET GROUP, LLC
added
337
3,051,570
3,749,820
-%
May 16, 2024
COMERICA BANK
added
9.3
960
3,787
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
new
-
528,789
528,789
-%
May 15, 2024
LUMINUS MANAGEMENT LLC
new
-
257,450
257,450
0.12%

1–10 of 44

Are Funds Buying or Selling LAB?

Are funds buying LAB calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own LAB
No. of Funds

Unveiling Standard BioTools Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 03, 2024
casdin capital, llc
17.29%
63,959,677
SC 13D/A
May 22, 2024
casdin capital, llc
17.22%
63,709,677
SC 13D/A
Mar 20, 2024
casdin capital, llc
16.19%
61,907,605
SC 13D/A
Mar 20, 2024
viking global investors lp
15.3%
58,651,170
SC 13G/A
Feb 26, 2024
millennium management llc
5.2%
15,037,065
SC 13G
Feb 14, 2024
indaba capital management, l.p.
9.9%
7,975,374
SC 13G/A
Feb 13, 2024
vanguard group inc
5.21%
4,133,939
SC 13G
Jan 12, 2024
neuberger berman group llc
1.51%
4,382,584
SC 13D/A
Jan 09, 2024
casdin capital, llc
16.17%
52,773,091
SC 13D/A
Jan 09, 2024
viking global investors lp
9.5%
29,106,365
SC 13G

Recent SEC filings of Standard BioTools Inc.

View All Filings
Date Filed Form Type Document
Jul 02, 2024
4
Insider Trading
Jul 02, 2024
4
Insider Trading
Jul 02, 2024
4
Insider Trading
Jul 02, 2024
4
Insider Trading
Jul 02, 2024
4
Insider Trading
Jul 02, 2024
4
Insider Trading
Jul 01, 2024
8-K
Current Report
Jun 27, 2024
EFFECT
EFFECT
Jun 26, 2024
3
Insider Trading
Jun 24, 2024
144
Notice of Insider Sale Intent

Standard BioTools Inc. News

Latest updates
MarketBeat6 hours ago

Standard BioTools Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue61.6%45,540,00028,188,00025,367,00027,666,00025,119,00027,021,00025,646,00018,777,00026,504,00038,265,00028,504,00031,018,00032,794,00044,608,00039,861,00026,058,00027,617,00032,440,00026,496,00028,196,00030,111,000
Gross Profit80.7%24,188,00013,385,00011,154,00013,602,00012,281,00011,167,0009,220,0004,427,000---------17,888,00014,038,00015,363,00016,990,000
Costs and Expenses-------------------27,854,00029,999,00031,196,000
Operating Expenses142.6%84,370,00034,771,00032,326,00031,051,00028,874,00025,145,50038,247,00042,990,00054,007,00049,524,00048,116,00048,286,00052,114,00061,512,00045,325,00039,784,00042,559,00041,621,00040,312,00042,832,00044,317,000
  S&GA Expenses119.8%46,943,00021,354,00022,292,00022,600,00021,295,00017,605,00026,340,00030,084,00030,875,00022,960,00024,072,00024,248,00027,608,00031,935,00022,655,00020,616,00022,695,00018,791,00020,729,00022,134,00022,824,000
  R&D Expenses130.4%15,980,0006,937,0006,370,0006,184,0006,429,0007,425,0008,486,00012,606,0008,865,0008,541,0009,209,0009,441,00010,753,00011,186,0008,128,0008,448,0008,699,0008,278,0007,125,0007,865,0008,372,000
EBITDA Margin-0.7%-0.63-0.62-0.63-0.72-1.29-1.89-1.60-1.43-0.90-0.43-0.46-0.36---------
Interest Expenses-87.7%190,0001,540,5001,223,0001,129,000232,0001,190,0001,049,0001,062,0001,030,0001,072,000968,000896,000887,000890,000885,000897,000900,000643,000444,000491,0002,701,000
Income Taxes157.8%100,000-173,00050,000300,000300,00063,500-713,000-1,600,000-574,000-826,500-1,422,000-500,000-1,671,000991,500-200,000-1,145,000-700,000370,000-1,200,000-1,143,00042,000
Earnings Before Taxes-60.6%-32,029,000-19,938,000-20,947,000-16,739,000-16,580,000-20,775,000-30,139,000-65,152,000-76,862,000-10,243,000-15,265,000-17,660,000-20,492,000-17,039,000-6,242,000-14,160,000-16,660,000-12,331,000-14,055,000-14,896,000-25,423,000
EBT Margin-1.4%-0.71-0.70-0.71-0.80-1.37-1.97-1.67-1.50-0.97-0.49-0.51-0.41---------
Net Income-62.6%-32,157,000-19,776,000-20,997,000-17,040,000-16,843,000-20,845,000-29,426,000-63,539,000-76,288,000-9,429,500-13,843,000-17,143,000-18,821,000-18,026,000-5,999,000-13,015,000-15,980,000-12,685,000-12,887,000-13,753,000-25,465,000
Net Income Margin-1.1%-0.71-0.70-0.72-0.80-1.35-1.94-1.64-1.46-0.94-0.45-0.50-0.40---------
Free Cashflow-347.4%-63,257,000-14,139,000-12,317,000-10,167,000-9,495,000-19,936,000-25,875,000-30,926,000-16,458,000-7,465,000-11,200,000-18,836,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets140.7%778323339356372390415441272275282289305325323282290265269284291
  Current Assets246.1%54815817118319520922925173.0072.0073.0078.0096.0011812378.0082.0096.0097.00107111
    Cash Equivalents455.2%28752.0080.0014211482.0061.0075.0031.0029.0030.0032.0051.0070.0073.0044.0036.0024.0028.0026.0066.00
  Inventory96.6%40.0021.0022.0022.0023.0021.0022.0023.0023.0021.0024.0025.0022.0020.0020.0019.0016.0014.0015.0014.0014.00
  Net PPE85.2%45.0024.0025.0025.0025.0026.0027.0027.0028.0028.0029.0028.0024.0018.008.008.008.008.008.008.008.00
  Goodwill0.0%1061061061061061061061061061061061061061071061062.00104104104104
Liabilities25.3%200160160158158161166167250181183180182186171150149111107111109
  Current Liabilities11.2%12210952.0047.0044.0043.0046.0043.0047.0050.0047.0053.0054.0054.0043.0038.0035.0033.0033.0037.0034.00
  Long Term Debt-47.5%0.001.00---55.00--36.00------------
    LT Debt, Current0.2%55.0055.00-------------------
    LT Debt, Non Current-47.5%0.001.00---55.00--36.00------------
Shareholder's Equity489.9%577-148---97.15-81.47--22.0095.0099.00109123139152133141154163173182
  Retained Earnings-7.8%-1,078-1,000-980-959-942-926-905-875-812-736-726-712-695-676-658-652-639-623-610-598-584
  Additional Paid-In Capital94.5%1,675861857853850847845841835831827822819816811786782778774771767
Shares Outstanding374.1%38080.0079.0079.0079.0079.0079.0078.0077.0077.0075.0075.00---------
Float----133---126---464---282---847-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-344.3%-62,476-14,061-11,412-9,329-8,485-19,181-24,611-29,988-15,590-7,002-9,494-14,664-12,901-3,733-4,599-2,790-4,295-5,519-4,548-5,013-20,130
  Share Based Compensation234.1%11,6113,4753,3863,1143,1481,6814,4944,6634,0424,3634,3203,7413,6774,0934,3583,6342,3663,1013,0292,9922,271
Cashflow From Investing2524.9%318,075-13,117-49,92640,12643,15440,24510,736-138,240-868-1,145-1,706-4,172-4,923-82213,21110,12617,460-5516,549-35,542-9,757
Cashflow From Financing-1867.4%-19,733-1,003-1,164-2,084-2,558-270-5.00212,95818,0757,2979,821-133-1,02643220,417511-5031,784-1811,040147
  Buy Backs9271.0%11,051-1204002,3752,466563---------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

LAB Income Statement

2024-03-31
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Total revenue$ 45,540$ 25,119
Cost of revenue:  
Total cost of revenue21,35212,838
Gross profit24,18812,281
Operating expenses:  
Research and development15,9806,429
Selling, general and administrative46,94321,295
Restructuring and related charges4,2841,150
Transaction-related expenses17,1630
Total operating expenses84,37028,874
Loss from operations(60,182)(16,593)
Bargain purchase gain25,213 
Interest income, net5,17472
Other expense, net(2,234)(59)
Loss before income taxes(32,029)(16,580)
Income tax expense(128)(263)
Net loss(32,157)(16,843)
Induced conversion of redeemable preferred stock(46,014)0
Net loss attributable to common stockholders$ (78,171)$ (16,843)
Net loss per share, basic (in dollars per share)$ (0.27)$ (0.21)
Net loss per share, diluted (in dollars per share)$ (0.27)$ (0.21)
Shares used in computing net loss per share attributable to common stockholders, basic (in shares)294,12579,080
Shares used in computing net loss per share attributable to common stockholders, diluted (in shares)294,12579,080
Product revenue  
Revenue:  
Total revenue$ 23,592$ 17,438
Cost of revenue:  
Total cost of revenue12,7819,990
Service revenue  
Revenue:  
Total revenue21,0276,881
Cost of revenue:  
Total cost of revenue8,5092,792
Collaboration and other revenue  
Revenue:  
Total revenue921800
Cost of revenue:  
Total cost of revenue$ 62$ 56

LAB Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 287,057$ 51,704
Short-term investments175,22563,191
Accounts receivable, net36,01219,660
Inventories, net40,35920,533
Prepaid expenses and other current assets8,9123,127
Total current assets547,565158,215
Inventory, non-current13,2620
Royalty receivable, non-current4,3520
Property and equipment, net44,78624,187
Operating lease right-of-use asset, net32,96630,663
Other non-current assets3,6732,285
Acquired intangible assets, net24,7941,400
Goodwill106,269106,317
Total assets777,667323,067
Current liabilities:  
Accounts payable13,1419,236
Accrued liabilities30,43021,019
Operating lease liabilities, current5,8344,323
Deferred revenue, current13,90611,607
Deferred grant income, current3,5873,612
Term loan, current0 
Convertible notes, current54,65654,530
Total current liabilities121,554109,327
Convertible notes, non-current299569
Term loan, non-current03,414
Deferred tax liability841841
Operating lease liabilities, non-current31,10830,374
Deferred revenue, non-current33,8543,520
Deferred grant income, non-current9,87510,755
Other non-current liabilities2,8201,065
Total liabilities200,351159,865
Commitments and contingencies (Note 8)
Mezzanine equity:  
Redeemable preferred stock: $0.001 par value; zero and 256 shares authorized at March 31, 2024 and December 31, 2023, respectively; aggregate liquidation preference of zero and $255,559 at March 31, 2024 and December 31, 2023, respectively0311,253
Stockholders' equity (deficit):  
Preferred stock: $0.001 par value, 10,000 and 9,744 shares authorized at March 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding at March 31, 2024 and December 31, 202300
Common stock: $0.001 par value, 600,000 shares authorized at March 31, 2024 and 400,000 shares authorized at December 31, 2023; 387,652 and 83,364 shares issued at March 31, 2024 and December 31, 2023, respectively; 380,400 and 80,232 shares outstanding at March 31, 2024 and December 31, 2023, respectively38783
Additional paid-in capital1,674,672860,816
Accumulated other comprehensive loss(1,792)(2,221)
Accumulated deficit(1,078,923)(1,000,752)
Treasury stock at cost: 7,251 and 3,132 shares at March 31, 2024 and December 31, 2023, respectively(17,028)(5,977)
Total stockholders' equity (deficit)577,316(148,051)
Total liabilities, mezzanine equity and stockholders' equity (deficit)$ 777,667$ 323,067
LAB
Standard BioTools Inc., together with its subsidiaries, creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEfluidigm.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES523

Standard BioTools Inc. Frequently Asked Questions


What is the ticker symbol for Standard BioTools Inc.? What does LAB stand for in stocks?

LAB is the stock ticker symbol of Standard BioTools Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Standard BioTools Inc. (LAB)?

As of Thu Jul 18 2024, market cap of Standard BioTools Inc. is 811.27 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LAB stock?

You can check LAB's fair value in chart for subscribers.

What is the fair value of LAB stock?

You can check LAB's fair value in chart for subscribers. The fair value of Standard BioTools Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Standard BioTools Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LAB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Standard BioTools Inc. a good stock to buy?

The fair value guage provides a quick view whether LAB is over valued or under valued. Whether Standard BioTools Inc. is cheap or expensive depends on the assumptions which impact Standard BioTools Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LAB.

What is Standard BioTools Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 18 2024, LAB's PE ratio (Price to Earnings) is -9.02 and Price to Sales (PS) ratio is 6.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LAB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Standard BioTools Inc.'s stock?

In the past 10 years, Standard BioTools Inc. has provided -0.225 (multiply by 100 for percentage) rate of return.